News Details

Contact

Rachel Darwin, Senior Manager, Public Relations

darwin@nccn.org, 267-622-6624

Blood Cancer Experts Discuss Latest Treatment Innovations at NCCN 2019 Annual Congress: Hematologic Malignancies™

Program includes debate and interactive case studies on emerging cancer care practices. #NCCNhem19.

SAN FRANCISCO, CA [September 10, 2019] — World-renowned experts on blood cancers are meeting in San Francisco on September 27-28, to help clinicians stay up-to-date on new, practice-changing strategies to manage patients with hematologic malignancies, at the NCCN 2019 Annual Congress: Hematologic Malignancies™, presented by the National Comprehensive Cancer Network® (NCCN®), and co-chaired by Ranjana H. Advani, MD, Saul Rosenberg Professor of Lymphoma, Stanford University School of Medicine and Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center. The Congress will address new, emerging, and novel therapeutic agents, diagnostics, and other advances in the management of blood cancers. The sessions will also explore the growing role of immunotherapies, biosimilars, personalized medicine, and chemotherapeutic options in a rapidly-changing landscape.

“Cancer care gets more complex every year. From risk assessment and molecular profiling to novel mechanisms of action, keeping up can be a challenge,” said Dr. Advani. “We’re eager to share expert consensus on the latest evidence, in order to help healthcare providers improve outcomes for their patients.”

“The clinical trials data and updated recommendations that we’re presenting can help clinicians to optimize and individualize treatment selection, minimize toxicities, and manage adverse events,” said Dr. Zelenetz. “Not only are attendees learning about the latest updates to various NCCN Guidelines for both rare and common blood cancers, but they also hear commentary and debate around any changes and the thinking that prompted them.”

The one-and-a-half day program features challenging case studies and panel discussions on updated management practices across a dozen topics related to blood cancers, including leukemias, lymphomas, multiple myeloma, plus rarer diseases. The congress opens with a debate on chemo-immunotherapy as a first-line treatment for chronic lymphocytic leukemia, and closes with a session on cytotoxic chemo-free first-line therapy for follicular lymphoma. A satellite symposium was recently added on approaches to individualized treatment for chronic lymphocytic leukemia, provided in collaboration with Clinical Care Options, LLC. Additional sessions focus on emerging immunotherapy practices like CAR T-Cell therapy, the role of personalized medicine in treating blood cancers, and what health care professionals need to know about therapeutic biosimilars.

The congress takes place at the Hilton San Francisco Union Square, and features the following faculty:

There is also a pre-congress session for nurses, which includes presentations on how to prevent infections in hematologic malignancies, managing bone health in patients with multiple myeloma, tumor lysis syndrome updates, and managing toxicities related to CAR T-Cell therapy. The forum features the following speakers:

Visit NCCN.org/hem for more information, and join the conversation online with the hashtag #NCCNhem19.

# # #